Pioneering Next-Generation
Antibodies for
Autoimmune Diseases

Who We Are


Omni Biotech Innovations is a Canadian based, early-stage drug discovery company focused on developing differentiated antibodies for the treatment of autoimmune diseases. The prevelance is high and rising, however, the current therapies still suffer from low remission rates and serious side effects. While bispecific & multi-specific antibody approaches have shown promise in cancer treatment, they remain under-explored in autoimmune disorders, presenting a unique opportunity for us.

We have all the conditions to develop best-in-class therapies:

Experienced Team

We are guided by experienced founders with complementary expertise in antibody engineering, immunology, BD, and drug development.

State-of-the-Art Facility

We operate from a 16,000 sq. ft. state-of-the-art facility, enabling advanced drug discovery and end-to-end development.

Patient-Driven Science

Our work is driven by our core mission to bring safe and effective medicines to autoimmune disease patients with the greatest unmet needs.

Our Business Model


WHY REINVENT THE WHEEL
- when you can accelerate to patient validation at lower cost?

We begin with a clear product concept and then strategically integrate validated IP, such as proven antibody fragments, with our proprietary platform to develop our products.

Innovation Funnel
Collaboration Funnel
Integration Funnel

Our Science


Built on Omni Biotech's proprietary platform & developed in collaboration with our partners, OBTI001 targets the root cause of autoimmunity to improve patient outcomes and enable effective long-term disease management.

OBTI001 is a novel multi-specific antibody therapy which selectively targets multiple B-cell populations and different receptor molecules using one drug. With the potential to treat a range of diseases—from more prevalent conditions like Rheumatoid Arthritis to rare diseases such as Myasthenia Gravis—OBTI001 offers a "pipeline in a product" market opportunity.

Our Pipeline


ASSET
TARGET
CONCEPT
LEAD OPTIMIZATION
IND ENABLING
PHASE 1
OBTI001
B-cell Targets
OBTI002
Undisclosed

Our Team